Natco Pharma completes transition of DASH Pharmaceuticals into Natco Pharma USA
Natco Pharma Limited shared that DASH Pharmaceuticals, a company that markets, sells and distributes generic pharmaceutical products, has officially transitioned to Natco Pharma USA, the U.S. subsidiary of Natco Pharma.
As of Jan. 2, all products marketed by the company will transition to the Natco Pharma USA label, with no changes to the current NDC numbers, the company said.
Natco Pharma USA is led by Subba Rao Mente, CEO.
Julie Trendowicz and Nick DiMaio, the former executive vice president and president of DASH, respectively, will assume the same roles under Natco Pharma USA.
[Read more: Natco receives FDA nod for 2 generics]
“By acquiring DASH, Natco Pharma has gained a strategic presence in the United States, connecting us directly with our valued customers in this crucial market,” said Mente. "This strategic move isn't just about growth; it's about bolstering our commitment to the U.S. pharmaceutical landscape.”
Since 2007, Natco Pharma has been active in the U.S. market, forging co-development and licensing partnerships with leading U.S. generic pharmaceutical companies. The company’s collaborative efforts have culminated in the successful development and launch of a range of first-to-market generics and complex formulations, including Lenalidomide Capsules, Glatiramer Acetate Pre-Filled Syringes, Liposomal Doxorubicin Vials, Oseltamivir Phosphate Capsules, Lanthanum Carbonate Chewable Tablets, Everolimus Tablets and Lapatinib Tablets.
[Read more: Natco, Breckenridge obtain FDA nod for generic Kyprolis]